It would mean a more rapid review by FDA, it could mean that we would get NCCN guidelines around gastric based on the published data even before its approval and it gives us a chance to do some preparation in the marketplace as well. So I think that becomes a factor in that regard. But I don’t expect that it’s going to have kind of a direct read through to the ongoing gastric trial.
Unidentified Analyst: Got it. This is very helpful. Thank you so much.
Operator: Our next question comes from Gary Nachman with BMO Capital Markets. Your line is now open.
Gary Nachman: Thanks. Good afternoon. Just back to Xywav, can you confirm that the strong reimbursement that you have already locked is going to be locked in for next year? Or is there still some uncertainty there for certain payers, depending on how the generic market forms for Xyrem. So how did those negotiations take place? And then generally, how much is the launch of IH helped overall awareness with narcolepsy as well as €“ you definitely continue to increase the number of patients treated in narcolepsy, not just in IH? Thanks.
Bruce Cozadd: Yes. Kim, do you want to take that?
Kim Sablich: Yes Sure. So in terms of 2023 coverage, I mean, what I can just say at this point in time is that we’ve got 90% commercial coverage for Xywav in both narcolepsy and idiopathic hypersomnia. And we think that bodes very well for us heading into next year. I believe you asked about the authorized generic really based on our conversations with payers as well as the strong contract that we have in place. We think the most likely scenario is going to be that payers will put the AG on the €“ put on their formularies in a comparable position to that of Xywav. In terms of IH helping the awareness of narcolepsy, look, what I’ll just say is it’s not so much just around the disease, but we are out there now wherever we can with the same sales force of the same customers largely due to that overlap that Bruce mentioned, a 90% overlap with the IH targets with those that we’re calling on already for narcolepsy, that we’re many times getting into discussions.
So we’ve essentially, in many cases, doubled the amount of promotion around the brand itself. So I do believe that, that just overall leads to momentum in both directions for both indications.
Operator: Please standby for our next question. Our next question comes from Annabel Samimy with Stifel. Your lie is now open.
Annabel Samimy: Just wanted to ask about Rylaze. When you think about the trajectory here, obviously, you had a really nice uptake. I’m a little bit curious to see if this is a new peak level, obviously, higher than Erwinaze. Is it going to be plateauing here given that you seem to have tapped the pediatric market? How should we think about growth from this point forward? Is it harder to get into LDL patients, AYA patients? X geographies? How should we think about the dynamic of growth? Is it a plateau? Or is it just a gradual growth from here?
Bruce Cozadd: Kim, you want to start with the US?
